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Abstract
The selection of point mutation at codon 164 (from isoleucine to leucine) of the dihydrofolate
reductase (DHFR) enzyme in Plasmodium falciparum is associated with high sulfadoxine /
pyrimethamine (SP) resistance. Using the yeast expression system that allows the detection of dhfr
allele present at low level, the presence of this mutation had previously been reported between
1998–1999 in Muheza, Tanzania, an area of high SP resistance. Eighty five P. falciparum isolates,
obtained from the same area between 2002 and 2003, were analysed for the presence of Leu-164
mutation, using standard protocol based on PCR-RFLP. None of the isolates had the Leu-164
mutation.
Background
The antifolate combination sulfadoxine /pyrimethamine
(SP) is currently the first line treatment for uncomplicated
falciparum malaria in several African countries. Pyrimeth-
amine (PM) and sulfadoxine  (SD) are inhibitors of dihy-
drofolate reductase (DHFR) and dihydropteroate
synthase (DHPS) respectively. The selection and rapid
spread of resistance to SP, which in some parts of East
Africa has reached a prevalence of more than 30% [1], has
already seriously compromised the therapeutic usefulness
of SP. A new antifolate combination of chlorproguanil
(CPG) and dapsone (DDS), known as Lapdap™ [2,3], has
now been developed. CPG is metabolised in vivo to its
active triazine metabolite, chlorcycloguanil (CCG),
which, like PM, inhibits the DHFR enzyme. DDS, like SD,
inhibits the activity of dhps. LapDap™ is effective in vivo
and retains efficacy against SP resistant infections [1], jus-
tifying the use of this drug as a replacement for SP.
Resistance to SP in Africa is attributable to parasites that
carry point mutations at codons 108, 51 and 59 of dhfr,
and resistance is augmented by point mutations at codon
437 and/or 540 of the dhps gene [4]. Experience in South
East Asia and South America shows that the continued use
of SP will eventually select for the mutation at codon 164
(from isoleucine to leucine). Once this occurs in Africa,
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parasites will become highly resistant to SP. This study
shows that the selection of this Leu-164 mutation will
also render the new antifolate combination CPG/DDS
ineffective [5]. Therefore, the occurrence in Africa of this
mutation would compromise the useful therapeutic life
(UTL) of the new antifolate combination CPG/DDS.
Although SP has been widely used in Africa, the Leu-164
mutation has not yet been reported using standard proto-
cols for the detection of this point mutation in dhfr (PCR-
RFLP and sequencing). For instance, a study carried out on
isolates collected during CPG/DDS trial in 1999, in Usam-
bara Mountains, Tanzania, did not detect the 164-Leu
using PCR-RFLP [6]. However, by using the yeast comple-
mentation approach, which is based on the expression of
plasmodium dhfr genes in yeast cells followed by the
selection of cells expressing highly resistant alleles, Hast-
ings and co-workers [7] have reported the presence of the
Leu-164 mutation in three SP resistant isolates collected
between 1998–1999, from Muheza, Tanzania – an area
with a high level of resistance resistance to SP [1]. This
finding indicates that parasites carrying dhfr alleles with
the Leu-164 mutation exist in Africa. As a consequence,
the UTL of the new combination CPG/DDS could be very
short.
Although the level of SP resistance is high in Muheza, this
drug is still used as the first line treatment because of the
lack of affordable alternative antimalarials. Under these
conditions, one would expect the selection and spread of
parasites carrying the Leu-164 mutation under SP pres-
sure, if this mutation conferred a biological advantage.
Treatment-mediated selection of the mutation would be
expected to raise the gene frequency to the point where
the dhfr alleles can be detected in Muheza using standard
protocols.
With this in mind, the presence of the Leu-164 mutation
are being monitored in isolates collected at Muheza from
1999, the year the Leu-164 mutation was detected in this
area, using the yeast cell complementation technique. In
this paper, are presented the results of the analysis of 85
recent isolates collected randomly from children suffering
from uncomplicated malaria at Muheza Designated Dis-
trict Hospital, Tanzania, between October 2002 to January
2003.
Materials and Methods
Patients were children under five years of age. Parent/care-
takers had given written informed consent to participate
in a separate on-going study assessing the effectiveness of
combination therapies of SP+amodiaquine, artemether/
lumefantrin and artesunate + amodiaquine. Approxi-
mately 50 µl of blood from the finger-prick, collected on
day 0 before treatment, were spotted onto filter paper, air-
dried and stored in plastic bags with silica gel at ambient
temperature until PCR analysis. The preparation of para-
site genomic material and the detection of point mutation
at codon 164 of dhfr were carried out as described else-
where [8]. Briefly, a small piece of blood-impregnated fil-
ter paper was snipped and put in a 0.5-ml microcentrifuge
tube containing 150 µl of absolute methanol for 15 min
at ambient temperature. Thereafter, the methanol was
poured off and the paper was allowed to dry. Fifty micro-
liters of sterilized water was then added to the tube, which
was heated at 95°C for 15 min in a PCR machine. Follow-
ing centrifugation (13,000 rpm [revolution per minute], 2
min), 2.5 to 5 µl of the solution was used as the template
for PCR analysis.
Results and Discussion
The results show that none of these isolates had mutation
at codon 164 of dhfr.
The number of isolates that were analysed is not repre-
sentative of the whole population of the parasites in this
area, but if this mutation is selected as the result of SP use,
then 4 years after the detection of the Leu-164 mutation
by yeast complementation technique, one might expect to
detect it by PCR-RFLP in randomly selected isolates: this is
not the case. In a similar study carried out recently on 277
isolates collected from several malaria endemic areas in
Africa, the Leu-164 mutation was not detected using the
standard PCR-RFLP protocol, in agreement with the find-
ings reported in this paper [9].
A possible explanation of these observations is that the
Leu-164 mutation detected by the yeast complementation
techniques may only represent normal and baseline poly-
morphism of the dhfr gene, and that this mutation does
not confer any selective advantage to the African parasite.
Thus, the low fitness of DHFR enzyme carrying the Leu-
164 mutation could explain the failure to select this muta-
tion. Therefore, the selection of the Leu-164 mutation in
South East Asia and South America may indicate that par-
asites from these areas developed compensatory mecha-
nisms to make up for the low efficiency of DHFR enzyme.
One of the most interesting explanations for the selection
of the Leu-164 mutation has come from a microsatellite
study carried out on isolates from South East Asia. Con-
trary to the case with isolates carrying Asn 108, Ile 51 and
Arg 59 mutations, those harboring the Leu-164 mutation
have derived from a single origin. This "single parasite"
has spread in South East Asia as a result of drug pressure
[10]. If the African parasites that carry the Leu-164 muta-
tion currently lack this putative compensatory mecha-
nism, this would explain why the Leu-164 mutation has
not yet been detected by standard methods. However, if
such parasites were to be imported into Africa while SP or
CPG/DDS is still in use, then the parasites would spread
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/46
Page 3 of 3
(page number not for citation purposes)
and render the antifolate antimalarial drugs ineffective.
This is a dangerous scenario for Africa. The question then
is: when, and how will such parasites be imported into
Africa? And, perhaps, whether it is possible to prevent this
importation? Whatever the mechanisms associated with
the selection of Leu-164 mutation may be, continuous
monitoring of this mutation should be carried out, espe-
cially in areas of high SP resistance, so as determine
whether the prevalence of resistant dhfr alleles harboring
this mutation is increasing.
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